Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

719927

Sigma-Aldrich

Resomer® RG 756 S, Poly(D,L-lactide-co-glycolide)

ester terminated, lactide:glycolide 75:25, Mw 76,000-115,000

Synonym(s):

PLGA

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
26780-50-7
UNSPSC Code:
12162002
NACRES:
NA.23

Quality Level

200

form

amorphous

feed ratio

lactide:glycolide 75:25

mol wt

Mw 76,000-115,000

degradation timeframe

<6 months

viscosity

0.71-1.0 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 49-55 °C

storage temp.

2-8°C

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

Application

Controlled release
Poly (lactic-co-glycolic acid) 75:25 copolymer may be used to design a controlled drug delivery implant.

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCV6334
MKCV6333
BCCH5996
BCCG5549
BCCG4154

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation.
Kamali H, et al.
Journal of drug delivery science and technology, 47, 95-105 (2018)
Shu-Chun Chuang et al.
Parasites & vectors, 6, 34-34 (2013-02-13)
Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or
Vanna Sanna et al.
International journal of nanomedicine, 7, 5501-5516 (2012-10-25)
Resveratrol, like other natural polyphenols, is an extremely photosensitive compound with low chemical stability, which limits the therapeutic application of its beneficial effects. The development of innovative formulation strategies, able to overcome physicochemical and pharmacokinetic limitations of this compound, may
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and
View All Related Papers

Articles

RESOMER® - Biodegradable Polymers for Sutures, Medical Devices, Drug Delivery Systems and Tissue Engineering

Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.

Poly(Glycerol Sebacate) in Tissue Engineering

Synthetic aliphatic polyesters dominate resorbable biomaterials in clinical use.

Biodegradable Polyester Nanoparticle Formation

AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.

Therapeutic Nanoparticles Harness Myeloid Cells for Brain Tumor-Targeted Delivery and Immunomodulation

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service